Sugi Predict

Sugi Predict / Compounds / SCHEMBL2431256

SCHEMBL2431256

SCHEMBL2431256

COC(=O)Cc1coc2cc(OC)ccc12

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.67
▸ KDM4E B2RXH2 4/20 0.67
▸ HPGD P15428 1/20 0.67
▸ MAPT P10636 4/20 0.66
▸ TDP1 Q9NUW8 1/20 0.66
▸ L3MBTL1 Q9Y468 3/20 0.65
▸ TSHR P16473 2/20 0.64
▸ GAA P10253 1/20 0.63
▸ NPSR1 Q6W5P4 1/20 0.63
▸ RAB9A P51151 4/20 0.62
▸ MEN1 O00255 2/20 0.62
▸ KMT2A Q03164 2/20 0.62
▸ PKM P14618 1/20 0.60
▸ MAPK1 P28482 1/20 0.60
▸ SMN1; SMN2 Q16637 1/20 0.60
▸ USP2 O75604 1/20 0.58
▸ LMNA P02545 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23117308 0.88 L3MBTL1 (0.67) ALDH1A1KDM4EMAPTTDP1L3MBTL1
SCHEMBL204937 0.87 MAPT (0.67) ALDH1A1KDM4EMAPTTDP1L3MBTL1
SCHEMBL1104010 0.86 MAPT (0.62) ALDH1A1KDM4EMAPTTDP1L3MBTL1
SCHEMBL1104011 0.86 MAPT (0.62) ALDH1A1KDM4EMAPTTDP1L3MBTL1
SCHEMBL437460 0.84 GAA (0.67) ALDH1A1KDM4EHPGDMAPTTDP1
SCHEMBL14564359 0.84 MAPT (0.71) ALDH1A1HPGDMAPTTDP1L3MBTL1
SCHEMBL21807610 0.83 MAPT (0.60) ALDH1A1KDM4EMAPTTDP1L3MBTL1
SCHEMBL25029852 0.83 MAPT (0.60) ALDH1A1KDM4EHPGDMAPTTDP1
SCHEMBL20539896 0.82 TSHR (0.50) ALDH1A1KDM4EHPGDMAPTTDP1
SCHEMBL4231514 0.82 MAPT (0.52) ALDH1A1KDM4EHPGDMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11377450-B2 Functionalized heterocycles as antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2022-07-05 — — US disclosed
EP-3852751-A1 FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS Enanta Pharmaceuticals, Inc. (US) 2021-07-28 — — EP disclosed
CN-112955142-A Functionalized heterocyclic compounds as antiviral agents 英安塔制药有限公司 2021-06-11 — — CN disclosed
US-20210115060-A1 FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS ENANTA PHARM INC (US) 2021-04-22 — — US disclosed
US-10865211-B2 Functionalized heterocycles as antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2020-12-15 — — US disclosed
US-20200095258-A1 FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2020-03-26 — — US disclosed
WO-2020061435-A1 FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. (US) 2020-03-26 — — WO disclosed
EP-2582674-B1 GPR120 RECEPTOR AGONISTS AND USES THEREOF CYMABAY THERAPEUTICS INC (US) 2014-10-01 — — EP disclosed
US-20140121246-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2014-05-01 — — US disclosed
US-8598374-B2 GPR120 receptor agonists and uses thereof METABOLEX, INC. (US) 2013-12-03 — — US disclosed
CN-101133056-B Antitumor compounds NAT HEALTH RESEARCH INSTITUTES 2010-12-01 — — CN disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 — — US disclosed
WO-2010080537-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-07-15 — — WO disclosed
US-7456289-B2 Anti-tumor compounds NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2008-11-25 — — US disclosed
CN-101133056-A Antitumor compounds NAT HEALTH RESEARCH INSTITUTES (CN) 2008-02-27 — — CN disclosed
EP-1838711-A2 ANTI-TUMOR COMPOUNDS National Health Research Institutes (TW) 2007-10-03 — — EP disclosed
US-20070191395-A1 Heterocyclic compounds having antifungal activity DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-08-16 — — US disclosed
EP-1717238-A1 FUNGICIDAL HETEROCYCLIC COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-11-02 — — EP disclosed
WO-2006074041-A2 ANTI-TUMOR COMPOUNDS NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2006-07-13 — — WO disclosed
US-20060148801-A1 Anti-tumor compounds NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2006-07-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11377450-B2 Functionalized heterocycles as antiviral agents HCCS, HAVCR2, HDGF ALDH1A1 2352/4885KDM4E 1899/4885HPGD 248/4885
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR ALDH1A1 3347/4885KDM4E 4479/4885HPGD 2073/4885
US-10865211-B2 Functionalized heterocycles as antiviral agents HCCS, HAVCR2, HDGF ALDH1A1 2352/4885KDM4E 1899/4885HPGD 248/4885
US-20070191395-A1 Heterocyclic compounds having antifungal activity ERG28, MANBA, MAN2B1 ALDH1A1 1357/4885KDM4E 3019/4885HPGD 1448/4885
US-20060148801-A1 Anti-tumor compounds TUBB1, TUBB3, TUBB ALDH1A1 2627/4885KDM4E 2204/4885HPGD 2405/4885
US-20140121246-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR ALDH1A1 3347/4885KDM4E 4479/4885HPGD 2073/4885
US-20210115060-A1 FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS HCCS, HAVCR2, HDGF ALDH1A1 2352/4885KDM4E 1899/4885HPGD 248/4885
US-20200095258-A1 FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS HCCS, HAVCR2, HDGF ALDH1A1 2352/4885KDM4E 1899/4885HPGD 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.